Eluxadoline Crystalline Form Alpha Prime Preparation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current crystalline forms of eluxadoline lack polymorphic and chemical stability, which is crucial for industrial-scale production and pharmaceutical applications, and there is a need for a process that produces high-purity products with minimal harmful compounds.
Innovation Solution
The development of a solvate form of eluxadoline using ketones such as acetone, 2-butanone, or 3-pentanone, which is then heated to a temperature between 20° C to 60° C to produce a polymorphically and chemically stable crystalline Form α′, allowing for improved handling and storage stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing crystalline forms of eluxadoline are used, then the compound can be produced and formulated, but the polymorphic and chemical stability is insufficient for reliable pharmaceutical applications
Solution Approach 1:
The patent applies parameter changes by modifying the crystallization conditions, specifically using ketone solvents (acetone, 2-butanone, or 3-pentanone) at controlled temperatures (20-60°C) to transform unstable crystalline forms into the stable Form α′. This parameter optimization resolves the stability contradiction by achieving reliable polymorphic form through controlled thermal and solvent parameters.
Solution Approach 2:
The invention utilizes phase transitions by heating the solvate form to induce transformation into the stable crystalline Form α′. This phase transition approach converts an unstable solid form into a stable polymorph, directly addressing the reliability and compositional stability contradiction in pharmaceutical applications.
2Manufacturing precision
If existing crystalline forms are used for industrial production, then manufacturing can proceed, but the purity is insufficient due to degradation under stressed conditions
Solution Approach 1:
The patent applies preliminary action by pre-forming the stable solvate intermediate before final crystallization to Form α′. This preliminary stabilization step prevents degradation during subsequent processing and storage, thereby improving manufacturing precision and reducing harmful degradation compounds in the final pharmaceutical product.
3Ease of manufacture
If unstable crystalline forms are used, then formulation processes can be simplified, but handling and storage become problematic due to poor stability
Solution Approach 1:
The invention effectively creates a stable, long-lasting crystalline form that replaces unstable intermediates. By establishing Form α′ as the final stable polymorph, the patent eliminates the need to handle unstable forms during storage and distribution, thereby improving ease of operation while maintaining formulation simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new solvate form of eluxadoline achieves enhanced stability and purity, with reduced degradation under stressed conditions, making it suitable for industrial production and pharmaceutical use.
Implementation Method 1
heating to a temperature between 20° C to 60° C to produce a polymorphically and chemically stable crystalline Form α′
Data Source
AI summary
Novel crystalline forms of Eluxadoline, having the formula (I), are described. Also described are the processes for the preparation of said crystalline forms.